Drug Trial Radar · NCT01014208
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Aug 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
447
Actual
Start
Mar 2010
Primary completion
Feb 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent disease, after first-line treatment with rituximab combined with an anthracycline-based chemotherapy regimen and be eligible for ASCT.
Conditions
- Lymphoma, Large-Cell, Diffuse
Interventions
OFATUMUMAB + DHAPDrug
3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
RITUXIMAB + DHAPDrug
3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival as Assessed by Independent ReviewersTime frame: From randomization until the date of stable disease after two cycles of salvage chemotherapy, progression, or death (assessed for up to 5 years)
Locations
173 sites in 26 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Sacramento, California
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Westwood, Kansas
GSK Investigational Site
Jackson, Mississippi
GSK Investigational Site
New York, New York
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
Chaple Hill, North Carolina
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Providence, Rhode Island
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
La Plata, Buenos Aires, Argentina
GSK Investigational Site
Graz, Austria
GSK Investigational Site
Innsbruck, Austria
GSK Investigational Site
Linz, Austria
GSK Investigational Site
Linz, Austria
GSK Investigational Site
Salzburg, Austria
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Bruges, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Hasselt, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Yvoir, Belgium
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Chengdu, China
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.